Fas binding to calmodulin regulates apoptosis in osteoclasts

Area of Science:

• Biochemistry and Molecular Biology
• Cell Biology
• Bone Biology

Background:

• Osteoporosis treatment aims to promote osteoclast apoptosis.
• Calmodulin, a key intracellular calcium receptor, influences osteoclast activity.
• Calmodulin antagonists have shown potential in treating bone loss.

Purpose of the Study:

• To investigate the mechanism by which calmodulin antagonists induce osteoclast apoptosis.
• To explore the role of calmodulin's interaction with the Fas receptor in this process.

Main Methods:

• Treatment of mouse osteoclasts with tamoxifen and trifluoperazine.
• Assessment of osteoclast apoptosis using dose-dependent assays.
• Analysis of calmodulin binding to the Fas receptor using glutathione S-transferase fusion proteins.
• Comparison of apoptosis sensitivity in osteoclasts from wild-type and Lpr(-cg) mice.

Main Results:

• Tamoxifen and trifluoperazine significantly increased osteoclast apoptosis in a dose-dependent manner.
• Calmodulin binds to the Fas receptor in osteoclasts, and this binding is reduced by trifluoperazine treatment.
• A mutation in the Fas death domain (V254N) reduced calmodulin binding.
• Osteoclasts with diminished calmodulin/Fas binding were more sensitive to calmodulin antagonist-induced apoptosis.

Conclusions:

• Calmodulin antagonists induce osteoclast apoptosis via a mechanism involving disrupted calmodulin binding to Fas.
• The interaction between calmodulin and Fas is crucial for regulating apoptosis sensitivity.
• Targeting the calmodulin/Fas interaction presents a potential therapeutic strategy for osteoporosis.